Silent Skin Epidemic Hiding In Plain Sight

Hidradenitis suppurativa affects millions of people, destroys quality of life, and remains one of the most chronically misunderstood diseases in all of dermatology — not because it is rare, but because medicine has been extraordinarily slow to look at it squarely.

At a Glance

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful abscesses, tunneling lesions, and scarring — and experts say it is far from rare, despite most people having never heard of it.
Patients routinely wait years for a correct diagnosis, a delay that reflects not the subtlety of the disease but the depth of its neglect in medical education and public awareness.
Federal research investment has historically been minuscule: by the end of 2018, only 0.1% of the National Institute of Arthritis and Musculoskeletal and Skin Diseases skin-disease budget had gone to HS, and just 17 dedicated clinical trials had been completed in the United States.
HS fits a well-documented pattern in inflammatory dermatology: disease burden and public visibility diverge sharply, especially when diagnosis is purely clinical, symptoms are stigmatized, and care is fragmented.

What Hidradenitis Suppurativa Actually Is

The name alone — hidradenitis suppurativa — signals why the condition gets lost in translation. It is a mouthful that most primary care physicians were never taught to say with confidence. Clinically, HS is a chronic, relapsing inflammatory follicular disease: it begins when hair follicles in intertriginous areas — the axillae, groin, perineum, inframammary folds, and buttocks — become occluded. Continued apocrine gland secretion behind that blockage drives cyst formation, trapping commensal bacteria. When those cysts rupture into the dermis, they trigger a cascade of innate and adaptive immune activation, suppuration, and — in advanced disease — the formation of epithelialized dermal tunnels lined with bacterial biofilm.^[14]

Those tunnels are the crux of why HS is so difficult to treat. Biofilm-rich sinus tracts sustain chronic inflammation that flares in response to hormonal and metabolic fluctuations, making the disease unpredictable in its timing and location. The inflammatory signature involves elevated cytokines — interleukin-1, IL-10, IL-17, tumor necrosis factor-alpha, and interferon-gamma — alongside dysregulated antimicrobial peptide production.^[12] There are no blood tests, no biopsies, no pathological markers that confirm the diagnosis; HS is defined entirely by its clinical features, which means a clinician who has never seen it will almost certainly misread it as recurrent boils, folliculitis, or something else altogether.

The Diagnostic Delay Problem

For patients, the consequences of that misreading are severe and cumulative. Researchers report that for many people with HS, it takes years to receive a correct diagnosis.^[4] In the interim, they are often treated with repeated courses of antibiotics for what their physicians call “infections,” or told the problem is poor hygiene — a misattribution that compounds the stigma already attached to lesions in the groin and axillae. The disease progresses during those years. Tunnels form. Scarring accumulates. The window for less invasive intervention narrows.

This diagnostic gap is not incidental; it reflects a structural failure. HS has no laboratory test to anchor recognition, training in its presentation has been thin across medical education, and the body regions it affects are ones clinicians may examine cursorily. The result is a condition that is common in the community but invisible in the clinic — a paradox that researchers and patient advocates have been working to close.

How Common Is “Not Rare”?

Experts are emphatic that HS is not a rare disease, even though most patients have never encountered the term before their diagnosis.^[5] Precise prevalence figures vary by study methodology and population, but estimates consistently place HS in a range that would make it one of the more prevalent chronic inflammatory skin diseases — comparable in scale to conditions like psoriasis that have attracted vastly more research attention and public recognition. Chronic non-infectious inflammatory skin conditions as a class affect roughly 20 to 25 percent of the global population, and HS sits within that burden alongside atopic dermatitis, psoriasis, urticaria, and lichen planus.^[1]

What makes HS distinctive within that group is not its rarity but the mismatch between its prevalence and its research footprint. Skin and subcutaneous diseases were the third most common global condition and the eighth leading cause of non-fatal health burden in 2021, yet they remain systematically underprioritized in public health policy.^[20] HS exemplifies this pattern at an acute level: the disease is common, burdensome, and stigmatized, and until recently it attracted almost no dedicated scientific investment.

Comorbidities and Systemic Burden

HS is not a skin-only disease. The chronic systemic inflammation it generates is associated with a constellation of comorbidities: metabolic syndrome, obesity, hypertension, hyperlipidemia, anxiety, and depression all appear at elevated rates in HS patients.^[12] This comorbidity burden matters for two reasons. First, it means the true cost of undertreating HS extends well beyond dermatology — into cardiology, endocrinology, and mental health. Second, it raises the mechanistic question of directionality: does HS drive metabolic dysfunction through sustained inflammatory signaling, or do shared upstream factors predispose patients to both? That question remains open, and answering it requires exactly the kind of longitudinal, well-funded research that has been missing.

The psychosocial dimension is equally significant. Chronic skin conditions carry well-documented mental health implications, and HS is particularly corrosive in this respect: its lesions appear in intimate body areas, it produces odor and drainage, and it is frequently misattributed to personal hygiene failures.^[9] Patients report fragmented healthcare experiences and disproportionate impacts on their education and employment. These are not peripheral concerns — they are central to why the disease demands more systematic attention than it has historically received.

A Pattern Dermatology Knows Well

HS is not the first inflammatory skin disease to follow this trajectory. Johns Hopkins researchers demonstrated in 2019 that prurigo nodularis — a disease of severely itchy, firm skin nodules — was far more prevalent than previously believed, affecting more than 72 per 100,000 people, yet had long been considered rare.^[19] Atopic dermatitis spent decades as a “pediatric” disease before the scale of adult disease burden forced a reckoning that ultimately drove the development of targeted biologics. Psoriasis, now served by nearly a dozen systemic therapies, once occupied a similarly neglected position in the research hierarchy.

The common thread is that visibility and burden diverge in inflammatory dermatology — reliably, and in predictable ways. Conditions that are stigmatized, that lack a diagnostic biomarker, that affect populations with less advocacy infrastructure, and that present on body areas clinicians examine infrequently tend to accumulate patient suffering quietly for years before the research community catches up. HS fits every element of that profile. The work now being done at institutions like the University of Washington and UNC, and the NIH’s explicit prioritization of HS research, represent the inflection point where that pattern finally begins to break.